drug
ublituximab
Marketedupdated 3mo agoby $TGTX TG THERAPEUTICS, INC.
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 3Antibody drug with a maximum clinical stage of Approval (across all indications), with 3 approved and 8 investigational indications.
all catalysts(5)
approval · 5
Dec 28, 2022
approval
$TGTX49.16-1.21%
BRIUMVI (UBLITUXIMAB-XIIY) — FDA approval
ublituximab
→
Oct 30, 2024
approval
$TGTX49.16-1.21%
BRIUMVI (UBLITUXIMAB-XIIY) — FDA approval
ublituximab
→
Aug 18, 2025
approval
$TGTX49.16-1.21%
BRIUMVI (UBLITUXIMAB-XIIY) — FDA approval
ublituximab
→
Aug 18, 2025
approval
$TGTX49.16-1.21%
BRIUMVI (UBLITUXIMAB-XIIY) — FDA approval
ublituximab
→
Jan 16, 2026
approval
$TGTX49.16-1.21%
BRIUMVI (UBLITUXIMAB-XIIY) — FDA approval
ublituximab
→
Trials studying ublituximab
- phase2Study to Evaluate the Safety and Efficacy of Ublituximab in Participants With Schizophrenia
- phase2A Study to Evaluate Pharmacokinetics (PK) and Safety of Subcutaneous (SC) Ublituximab Administered at Various Injection Sites and Relative Bioavailability Via Autoinjector (AI) Versus Syringe Subcutaneously in Participants With Multiple Sclerosis (MS)
- phase3Study to Assess Effects of Ublituximab in Pediatric Participants With Relapsing Forms of Multiple Sclerosis
- phase3An Extension Study of Ublituximab in Participants With Relapsing Multiple Sclerosis
- phase3Study to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of a Modified Regimen of Ublituximab
- phase4Study of Ublituximab for Ocrelizumab Wearing-Off in Multiple Sclerosis
- phase2Ublituximab in Autoantibody Positive Immune Mediated Necrotizing Myopathy
- phase3A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, Radiological and Clinical Effects of Subcutaneous Ublituximab in Participants With Relapsing Multiple Sclerosis (RMS)
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 40m ago
Found something off?
comments(0)
5-min edit window · permanent after that